58 related articles for article (PubMed ID: 24517736)
1. Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy?
Keita M; Perbost I; Pugliese-Wehrlen S; Abel S; Pugliese P; Enel P; Cuzin L; Lang T; Delpierre C;
AIDS Care; 2014; 26(8):1058-69. PubMed ID: 24517736
[TBL] [Abstract][Full Text] [Related]
2. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
[TBL] [Abstract][Full Text] [Related]
3. Abacavir (Ziagen(®)) use between 2003 and 2008 in France according to the electronic medical record NADIS(®).
Dellamonica P; Katlama C; Lévy-Bachelot L; Daures JP; Finkielsztejn L
Med Mal Infect; 2013 Dec; 43(11-12):467-74. PubMed ID: 24262915
[TBL] [Abstract][Full Text] [Related]
4. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
5. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
[TBL] [Abstract][Full Text] [Related]
6. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
[TBL] [Abstract][Full Text] [Related]
7. How reliable is an undetectable viral load?
Combescure C; Vallier N; Ledergerber B; Cavassini M; Furrer H; Rauch A; Battegay M; Bernasconi E; Vernazza P; Hirschel B;
HIV Med; 2009 Sep; 10(8):470-6. PubMed ID: 19459990
[TBL] [Abstract][Full Text] [Related]
8. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.
Piroth L; Fournel I; Mahy S; Yazdanpanah Y; Rey D; Rabaud C; Faller JP; Hoen B; Fardeheb M; Quantin C; Chavanet P; Binquet C;
Epidemiol Infect; 2011 Dec; 139(12):1835-44. PubMed ID: 21232172
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
10. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
11. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
12. Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM; Armenia D; Alteri C; Flandre P; Calcagno A; Santoro M; Gori C; Fabeni L; Bellagamba R; Borghi V; Forbici F; Latini A; Palamara G; Libertone R; Tozzi V; Boumis E; Tommasi C; Pinnetti C; Ammassari A; Nicastri E; Buonomini A; Svicher V; Andreoni M; Narciso P; Mussini C; Antinori A; Ceccherini-Silberstein F; Di Perri G; Perno CF
Antivir Ther; 2013; 18(7):867-76. PubMed ID: 23343501
[TBL] [Abstract][Full Text] [Related]
13. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.
Guiguet M; Ghosn J; Duvivier C; Meynard JL; Gras G; Partisani M; Teicher E; Mahamat A; Rodenbourg F; Launay O; Costagliola D;
AIDS; 2012 Nov; 26(18):2345-50. PubMed ID: 22695301
[TBL] [Abstract][Full Text] [Related]
14. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.
Smit C; Lindenburg K; Geskus RB; Brinkman K; Coutinho RA; Prins M
Addiction; 2006 Mar; 101(3):433-40. PubMed ID: 16499516
[TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
18. Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up.
Knobel H; Urbina O; González A; Sorlí ML; Montero M; Carmona A; Guelar A
HIV Med; 2009 Jul; 10(6):364-9. PubMed ID: 19490179
[TBL] [Abstract][Full Text] [Related]
19. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
[TBL] [Abstract][Full Text] [Related]
20. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]